Disclosed is the use of a non-infectious antigenic composition in the manufacture of a medicament for eliciting an immune response in a human patient suffering from cancer to treat the cancer situated in a specific organ or specific tissue of the human patient, or to prevent or ameliorate the metastasis of the cancer from a primary site in the human patient to a secondary site in the specific organ or specific tissue of the human patient, wherein: - the non-infectious antigenic composition comprises at least one attenuated bacteria of a species or strain that is pathogenic in the specific organ or tissue of the human patient； - the non-infectious antigenic composition does not produce infection in the specific organ or specific tissue of the human patient； and wherein, - the attenuated bacteria is an Escherichia coli and the specific organ or tissue is selected from the group consisting of: intra-abdominal lymph nodes； haematological tissues or organs； bone； brain； eye or orbit； small bowel； colon； rectum； anus； perineum； liver； gall bladder； biliary tract； pancreas； spleen； adrenal gland； kidney； ureter； bladder； peritoneum； prostate； testicle； ovary； adnexa； uterus； and vagina.
